Cost of Revenue Trends: Novo Nordisk A/S vs AbbVie Inc.

Pharma Giants' Cost Trends: Novo Nordisk vs. AbbVie

__timestamp	AbbVie Inc.	Novo Nordisk A/S
Wednesday, January 1, 2014	4426000000	14562000000
Thursday, January 1, 2015	4500000000	16188000000
Friday, January 1, 2016	5833000000	17183000000
Sunday, January 1, 2017	7040000000	17632000000
Monday, January 1, 2018	7718000000	17617000000
Tuesday, January 1, 2019	7439000000	20088000000
Wednesday, January 1, 2020	15387000000	20932000000
Friday, January 1, 2021	17446000000	23658000000
Saturday, January 1, 2022	17414000000	28448000000
Sunday, January 1, 2023	20415000000	35765000000

Igniting the spark of knowledge

Cost of Revenue Trends: A Tale of Two Giants

In the ever-evolving pharmaceutical industry, Novo Nordisk A/S and AbbVie Inc. have emerged as titans, each with a unique trajectory in cost management. From 2014 to 2023, Novo Nordisk's cost of revenue surged by approximately 145%, reflecting its aggressive expansion and innovation in diabetes care. Meanwhile, AbbVie Inc. experienced a 360% increase, driven by its strategic acquisitions and robust pipeline in immunology and oncology.

A Decade of Growth

Novo Nordisk consistently maintained a higher cost of revenue, peaking in 2023 with a 68% lead over AbbVie. This trend underscores Novo Nordisk's commitment to scaling its operations globally. Conversely, AbbVie's sharp rise in costs post-2019 highlights its investment in diversifying its product portfolio.

Strategic Implications

These trends reveal the strategic priorities of each company, with Novo Nordisk focusing on organic growth and AbbVie leveraging acquisitions to fuel its expansion.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025